Business Context and Reporting Period
This Form 8-K is a current report filed by Rani Therapeutics Holdings, Inc. on August 4, 2026, covering events occurring on August 1, 2026. The company is a Delaware corporation with its principal executive offices in San Jose, California, and its Class A Common Stock trades on The Nasdaq Stock Market under the symbol "RANI". The filing is primarily focused on corporate governance changes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed in this filing is the appointment of a new director to the Board of Directors:
- Appointment: Michelle Gilson was appointed to the Board of Directors, effective immediately on August 1, 2026.
- Committee Role: Ms. Gilson was simultaneously appointed as the Chair of the Audit Committee.
- Term: Her appointment lasts until the earlier of the Company's next annual meeting of stockholders, the appointment of her successor, or her death, resignation, or removal.
Management Commentary, Risks, and Unusual Items
Director Background: Ms. Gilson brings significant experience in biotechnology finance. She served as Chief Financial Officer of Arcellx, Inc. from May 2022 until its acquisition by Gilead Sciences, Inc. in April 2026. Prior to that, she held senior roles at Canaccord Genuity Group Inc., Jefferies LLC, Nomura Group, Oppenheimer & Co., Inc., and Goldman Sachs, focusing on healthcare and biotechnology sectors.
Compensation and Agreements: Ms. Gilson will receive compensation as a non-employee director in accordance with the Company's existing Non-Employee Director Compensation Policy. The Company will also enter into a standard form of indemnification agreement with her.
Risks and Contingencies: The filing states there are no arrangements or understandings between the Company and Ms. Gilson other than those disclosed. There is no family relationship between Ms. Gilson and other directors or officers, and she has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Michelle Gilson's appointment (August 1, 2026) and her role as Audit Committee Chair.
- Review the Company's Non-Employee Director Compensation Policy (referenced as Exhibit 10.1 to the May 15, 2026 Form 10-Q) to understand the specific compensation structure for Ms. Gilson.
- Confirm the terms of the standard Indemnification Agreement (referenced as Exhibit 10.4 to the July 9, 2021 Form S-1) applicable to Ms. Gilson.
- Assess the strategic impact of adding a director with recent CFO experience at a biotech firm (Arcellx) acquired by a major pharmaceutical company (Gilead).